Tara Spence

Dr. Tara Spence

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
TSTara Spence
Tara Spence
ADAdrian M. Dubuc
Adrian M. Dubuc

20 January 2026 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
JPJulia N.C. Parlow
Julia N.C. Parlow
ZHZeid Hamadeh
Zeid Hamadeh
NSNicolas Salcedo-Porras
Nicolas Salcedo-Porras
FAFatma AlBulushi
Fatma AlBulushi
EMEric McGinnis
Eric McGinnis
TSTara Spence
Tara Spence

7 January 2026 in Trends in Cancer
Verified
Journal Article
Closed access
MFMostafa Fatehi
Mostafa Fatehi
KTKira Nicole Tosefsky
Kira Nicole Tosefsky
SMSerge Makarenko
Serge Makarenko
KMKarina Chornenka Martin
Karina Chornenka Martin
RHRebecca Harrison
Rebecca Harrison
Stephen YipStephen Yip
Stephen Yip

12 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JPJulia N C Parlow
Julia N C Parlow
NSNicolas Salcedo-Porras
Nicolas Salcedo-Porras
FAFatma AlBulushi
Fatma AlBulushi
Stephen YipStephen Yip
Stephen Yip
EMEric McGinnis
Eric McGinnis
TSTara Spence
Tara Spence
Background/Objectives: Genomic alterations play a central role in diagnosis, prognostication, and therapeutic planning for hematolymphoid malignancies. At our tertiary care center, frontline genomic testing relies on optical genome mapping, karyotyping, and fluorescence in situ hybridization, with targeted next-generation sequencing (NGS) performed externally. To provide more comprehensive genomic profiling, we evaluated two large-panel NGS platforms and subsequently performed a clinical validation of the selected assay. Methods: The Illumina PanHeme DNA panel and the SOPHiA Genetics Community Myeloid Solution were compared using 24 bone marrow aspirate specimens with previously characterized alterations, including single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variants (CNVs). The selected panel underwent full analytical validation using 60 specimens. Results: Both panels demonstrated excellent concordance for SNVs and indels, with comparable analytical performance and workflow. CNV calling with SOPHiA was notably strong. Platform selection was influenced by practical considerations, including panel content and cost, leading to a preference for further evaluation of the Illumina assay. Clinical validation of the Illumina PanHeme DNA panel, along with a complementary RNA Exome panel, was subsequently performed. Sequence variant detection showed 100% concordance with orthogonal testing, while CNV detection was variable, reflecting known limitations of targeted NGS. The RNA panel detected all expected fusion transcripts. Conclusions: These findings demonstrate robust analytical performance of both evaluated DNA panels. Clinical validation of the Illumina PanHeme DNA and RNA Exome assays supports their use for comprehensive molecular profiling of hematologic malignancies.

11 November 2026 in Canadian Journal of Medical Specialties
Verified
Journal Article
Open access
PDF file
JPJulia N C Parlow
Julia N C Parlow
TSTara Spence
Tara Spence
Optical genome mapping (OGM) provides high-resolution, genome-wide detection of structural and copy number variants in hematologic malignancies and has demonstrated increased diagnostic yield compared with conventional cytogenetics. Despite these advantages, karyotyping remains widely used in acute leukemia diagnostics. We examine the practical and analytical factors underlying continued reliance on conventional cytogenetic testing, with particular emphasis on turnaround time. At our institution, OGM has been implemented alongside karyotyping since 2023 and has been applied to more than 800 cases. While OGM improves detection of cryptic and complex genomic rearrangements, conventional karyotyping continues to deliver significantly faster preliminary and final results, which directly impact early clinical decision-making in acute leukemia. We describe our integrated diagnostic workflow and compare operational performance between modalities, highlighting trade-offs between genomic resolution and reporting speed. These findings support a complementary role for OGM while reinforcing the ongoing clinical necessity of rapid karyotyping in frontline acute leukemia diagnostics.

6 November 2026 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
FAFatma AlBulushi
Fatma AlBulushi
NSNicolas Salcedo-Porras
Nicolas Salcedo-Porras
JPJulia N C Parlow
Julia N C Parlow
CNChristine Nast
Christine Nast
ZHZeid Hamadeh
Zeid Hamadeh
EMEric McGinnis
Eric McGinnis
Accurate identification of KMT2A::MLLT10 fusions is essential for diagnostic classification and prognostication in acute myeloid leukemia and can guide therapeutic decision making. Detection of these fusions is diagnostically challenging due to the frequently cryptic and structurally complex nature of these events. In this study, we evaluated acute leukemia cases undergoing diagnostic workup with karyotyping and optical genome mapping (OGM), identified cases with KMT2A::MLLT10 fusions and retrospectively analyzed the structural events. During the period from September 2023 to April 2025, a total of five acute myeloid leukemia cases were identified which had a KMT2A::MLLT10 fusion. While OGM identified a KMT2A::MLLT10 rearrangement in all five cases, karyotype analysis showed no evidence of a rearrangement involving the KMT2A locus on 11q23 in four cases and fluorescence in situ hybridization (FISH) showed a normal signal pattern using a KMT2A break‐apart probe in interphase nuclei in three cases. Additionally, OGM revealed the complexity of the rearrangement events underlying fusion formation, generally including inversions ranging from less than 1 megabase to over 20 megabases in size along with variably sized deletions around the translocation breakpoints. Our study reveals that KMT2A::MLLT10 rearrangements are characterized by complex, multi‐break events with variable sizes of inversions of the translocated segments resulting in in‐frame fusions. These events were often difficult to detect by standard karyotype and interphase FISH, highlighting the value of high‐resolution methods like OGM in resolving these structurally complex events.